Advanced search
Publication Cover
Critical Reviews in Toxicology Volume 37, 2007 - Issue 8
Submit an article Journal homepage
10,051
Views
211
CrossRef citations to date
0
Altmetric
Research Article

Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological Studies

B. A. Magnuson Burdock Group, Washington, DC, USA
,
G. A. Burdock Burdock Group, Vero Beach, Florida, USA
,
J. Doull University of Kansas Medical School, Kansas City, Kansas, USA
,
R. M. Kroes Institute for Risk Assessment Sciences, Utrecht, The Netherlands
,
G. M. Marsh University of Pittsburgh, Pittsburgh, Pennsylvania, USA
,
M. W. Pariza University of Wisconsin, Madison, Wisconsin, USA
,
P. S. Spencer Oregon Health and Science University, Portland, Oregon, USA
,
W. J. Waddell University of Louisville Medical School, Louisville, Kentucky, USA
,
R. Walker University of Surrey, Guilford, Great Britain
&
G. M. Williams New York Medical College, Valhalla, New York, USA
 show all
Pages 629-727 | Published online: 10 Oct 2008

REFERENCES

  • ADA. Use of nutritive and nonnutritive sweeteners. American Dietetic Association. 2002, http://www.eatright.org/cps/rde/xchg/ada/hs.xsl/advocacy_adap0598_ENU_HTML.htm (site visited on May 3, 2006)
  • Adibi S. A., Fogel M. R., Agrawal R. M. Comparison of free amino acid and dipeptide absorption in the jejunum of sprue patients. Gastroenterology 1974; 67: 586–591
  • Alaimo K., McDowell M. A., Briefel R. R., Bischof A. M., Caughman C. R., Loria C. M., Johnson C. L. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988–1991. Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/National Center for Health Statistics. U.S. Department of Health and Human Services. Public Health Service. Centers for Disease Control and Prevention. National Center for Health Statistics, Washington, DC 1994; 1–28, Report Number 258
  • An-Pyo Center. Histopathological examination in a carcinogenicity study of SC-18862 in Slc: Wistar Rats. Foods, Drugs and Pesticides (An-Pyo Center), ShizuokaJapan 2006, Final Report Biosafety Research Center
  • Andress J. M., Martinez T., Youkilis G. E-045. SC-19192: Acute toxicity studies in the rat, mouse, and rabbit. G.S. Searle & Co., Skokie, Illinois 1973a
  • Andress J. M., Martinez T., Youkilis G. E-046. SC-18862: Acute toxicity studies in the rat, mouse, and rabbit. G.S. Searle & Co., Skokie, Illinois 1973b
  • Anonymous. Sweetener intakes. Food and Chemical Toxicology 1991; 29: 71–72
  • Anonymous. Aspartame. Food & Nutrition. Health Canada. 2005, http://www.hc-sc.gc.ca/fn-an/securit/facts-faits/aspartame/aspartame01_e.html (site visited on May 17, 2006)
  • Anonymous. Chronic Fatigue Syndrome. Centers for Disease Control and Prevention (CDC). 2006, http://www.cdc.gov/ncidod/diseases/cfs/about/causes.htm (site visited on March 31, 2006)
  • Anthon G. E., Barrett D. M. Characterization of the temperature activation of pectin methylesterase in green beans and tomatoes. Journal of Agricultural and Food Chemistry 2006; 54: 204–211
  • Arcella D., Le Donne C., Piccinelli R., Leclercq C. Dietary estimated intake of intense sweeteners by Italian teenagers. Present levels and projections derived from the INRAN-RM-2001 food survey. Food and Chemical Toxicology 2004; 42: 677–685
  • Aspinall R. L., Saunders R. N., Pautsch W. F., Nutting E. F. The biological properties of aspartame. V. Effects on a variety of physiological parameters related to inflammation and metabolism. Journal of Environmental Pathology and Toxicology 1980; 3: 387–395
  • Baines C. J. Table top artificial sweeteners. Current use in Canada. Journal of the Canadian Dental Association 1985; 51: 427–428
  • Baker G. L. Aspartame ingestion during lactation. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 565–577
  • Baldrick P. Carcinogenicity evaluation: Comparison of tumor data from dual control groups in the Sprague-Dawley rat. Toxicologic Pathology 2005; 33: 283–291
  • Bar A., Biermann C. Intake of intense sweeteners in Germany. Zeitschrift fur Ernahrungswissenschaft 1992; 31: 25–39
  • Barceloux D. G., Bond G. R., Krenzelok E. P., Cooper H., Vale J. A. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. Clinical Toxicology 2002; 40: 415–446
  • Bell L. N., Labuza T. P. Aspartame degradation as a function of “water activity.”. Advances in Experimental Medicine and Biology 1991; 302: 337–349
  • Bell L. N., Labuza T. P. Aspartame stability in commercially sterilized flavored dairy beverages. Journal of Dairy Science 1994; 77: 34–38
  • Bianchi R. G., Muir E. T., Cook D. L., Nutting E. F. The biological properties of aspartame. II. Actions involving the gastrointestinal system. Journal of Environmental Pathology and Toxicology 1980; 3: 355–362
  • Biddle C. The neurobiology of the human febrile response. AANA Journal 2006; 74: 145–150
  • Bizarre S., Janshekar H., Kishi A. High-Intensity Sweeteners. 2006, CEH Marketing Research Report, Report Number: 543.6500, November 2003. (cited in HSPE, 2005)
  • Blair A., Stewart P., O'Berg M., Gaffey W., Waltrath J., Ward J., Bales R., Kaplan S., Cubit D. Mortality among industrial workers exposed to formaldehyde. Journal of the National Cancer Institute 1986; 76: 1071–1084
  • Blair A., Stewart P. A., Zaebst D. D., Pottern L., Zey J. N., Bloom T. F., Miller B., Ward E., Lubin J. Mortality of industrial workers exposed to acrylonitrile. Scandinavian Journal of Work, Environment and Health 1998; 24: 25–41, (Suppl. 2)
  • Blumenthal H. J., Vance D. A. Chewing gum headaches. Headache 1997; 37: 665–666
  • Bottomley J. M. Complementary nutrition in treating urinary incontinence. Topics in Geriatric Rehabilitation 2000; 16: 61–77
  • Bowles C. A. Mutagenic study in rats SC-18862. Hazelton Laboratories, Inc., Falls Church, VA 1970, Final Report. Report 700-234
  • Brunner R. L., Vorhees C. V., Kinney L., Butcher R. E. Aspartame: Assessment of developmental psychotoxicity of a new artificial sweetener. Neurobehavioral Toxicology 1979; 1: 79–86
  • Bryan G. T. Artificial sweeteners and bladder cancer: Assessment of potential urinary bladder carcinogenicity of aspartame and its diketopiperazine derivative in mice. Food Science and Technology Research 1984a; 12: 321–348
  • Bryan G. T. Artificial sweeteners and bladder cancer: assessment of potential uring bladder carcinogenicity of aspartame and its diketopiperazine derivative in mice. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984b; 321–362
  • Budavari S., O'Neil M., Smith A., Heckelman P., Obenchain J. Aspartame. The Merck Index. Chapman & Hall, Boca Raton, FL 1999, CD-ROM
  • Bunin G. R., Kushi L. H., Gallagher P. R., Rorke-Adams L. B., McBride M. L., Cnaan A. Maternal diet during pregnancy and its association with medulloblastoma in children: A children's oncology group study (United States). Cancer Causes and Control 2005; 16: 877–891
  • Burdock G. A. Aspartame. Encyclopedia of Food and Color Additives. CRC Press, Boca Raton, FL 1997; Vol. I: 215–218
  • Burdock G. A. Aspartame. Fenaroli's Handbook of Flavor Ingredients. 5th Edition. CRC Press, Boca Raton, FL 2005; 118–119
  • Burgert S. L., Andersen D. W., Stegink L. D., Takeuchi H., Schedl H. P. Metabolism of aspartame and its L-phenylalanine methyl ester decomposition product by the porcine gut. Metabolism: Clinical and Experimental 1991; 40: 612–618
  • Burns T. S., Stargel W. W., Hurwitz A. Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg). in capsules and solution. Metabolism: Clinical and Experimental 1990; 39: 1200–1203
  • Burns T. S., Stargel W. W., Tschanz C., Kotsonis F. N., Hurwitz A. Aspartame and sucrose produce a similar increase in the plasma phenylalanine to large neutral amino acid ratio in healthy subjects. Pharmacology 1991; 43: 210–219
  • Burton E. G., Dal Monte P., Spears C., Frank P., Oppermann J. A. Absorption by the rhesus monkey of phenylalanine methyl ester and species differences in its metabolism by blood, plasma and intestinal mucosa. Journal of Nutrition 1984; 114: 1940–1945
  • Burton E. G., Schoenhard G. L., Hill J. A., Schmidt R. E., Hribar J. D., Kotsonis F. N., Oppermann J. A. Identification of N-beta-L-aspartyl-L-phenylalanine as a normal constituent of human plasma and urine. Journal of Nutrition 1989; 119: 713–721
  • Butchko H. H., Kotsonis F. N. Acceptable daily intake vs actual intake: The aspartame example. Journal of the American College of Nutrition 1991; 10: 258–266
  • Butchko H. H., Stargel W. W. Aspartame: Scientific evaluation in the postmarketing period. Regulatory Toxicology and Pharmacology 2001; 34: 221–233
  • Butchko H. H., Stargel W. W., Comer C. P., Mayhew D. A., Benninger C., Blackburn G. L., de Sonneville L. M.J., Geha R. S., Hertelendy Z., Koestner A., Leon A. S., Liepa G. U., McMartin K. E., Mendenhall C. L., Munro I. C., Novotny E. J., Renwick A. G., Schiffman S. S., Schomer D. L., Shaywitz B. A., Spiers P. A., Tephly T. R., Thomas J. A., Trefz F. K. Aspartame: Review of safety. Regulatory Toxicology and Pharmacology 2002a; 35: S1–93
  • Butchko H. H., Stargel W. W., Comer C. P., Mayhew D. A., Benninger C., Blackburn G. L., de Sonneville L. M.J., Geha R. S., Hertelendy Z., Koestner A., Leon A. S., Liepa G. U., McMartin K. Metabolism of aspartame. Regulatory Toxicology and Pharmacology 2002b; 35: S17–S25
  • Caballero B., Mahon B. E., Rohr F. J., Levy H. L., Wurtman R. J. Plasma amino acid levels after single-dose aspartame consumption in phenylketonuria, mild hyperphenylalaninemia, and heterozygous state for phenylketonuria. Journal of Pediatrics 1986; 109: 668–671
  • Cain D. P., Boon F., Bevan M. Failure of aspartame to affect seizure susceptibility in kindled rats. Neuropharmacology 1989; 28: 433–435
  • Camfield P. R., Camfield C. S., Dooley J. M., Gordon K., Jollymore S., Weaver D. F. Aspartame exacerbates EEG spike-wave discharge in children with generalized absence epilepsy: A double-blind controlled study. Neurology 1992; 42: 1000–1003
  • Capen C. C., Dybing E., Rice J. M., Wilbourn J. D. Species differences in thyroid, kidney and urinary bladder carcinogenesis. IARC, Lyon 1999, IARC Scientific Publications No. 147
  • Carlson H. E., Shah J. H. Aspartame and its constituent amino acids: Effects on prolactin, cortisol, growth hormone, insulin, and glucose in normal humans. American Journal of Clinical Nutrition 1989; 49: 427–432
  • CFR. 2005, CFR 21 Food and Drugs. Sec. 172.804 Aspartame. Food additives permitted for direct addition to food for human consumption
  • ChemIDplus Advanced. National Library of Medicine, Aspartame 2004, http://chem.sis.nlm.nih.gov/chemidplus (site visited on January 16, 2006)
  • Cho E. S., Coon J. D., Stegink L. D. Plasma and urine diketopiperazine concentrations in normal adults ingesting large quantities of aspartame. Food and Chemical Toxicology 1987; 25: 499–504
  • Christian B., McConnaughey K., Bethea E., Brantley S., Coffey A., Hammond L., Harrell S., Metcalf K., Muehlenbein D., Spruill W., Brinson L., McConnaughey M. Chronic aspartame affects T-maze performance, brain cholinergic receptors and Na+,K+-ATPase in rats. Pharmacology, Biochemistry, and Behavior 2004; 78: 121–127
  • Chung M. S., Suh H. J., Yoo W., Choi S. H., Cho Y. J., Cho Y. H., Kim C. J. Daily intake assessment of saccharin, stevioside, D-sorbitol and aspartame from various processed foods in Korea. Food Additives and Contaminants 2005; 22: 1087–1097
  • CICAD. Formaldehyde. World Health Organization (WHO), Geneva 2002, Concise International Chemical Assessment Document (CICAD). No. 40. First draft prepared by Liteplo, R.G., Beauchamp, M.E., Meek, M.E., and Chenier, R.
  • Clark M. L., Fairclough P. D., Silk D. B.A. Amino acid and peptide absorption in patients with coeliac disease. Zeitschrift fur Ernahrungswissenschaft 1977; 20: 32–37
  • Clary J. J., Sullivan J. B., Jr. Formaldehyde. Clinical Environmental Health and Toxic Exposures, J. B. Sullivan, G. R. Krieger. Lippincott Williams & Wilkins, Philadelphia, PA 1999; 1007–1014
  • Cloninger M. R., Baldwin R. E. Aspartylphenylalanine methyl ester: A low-calorie sweetener. Science 1970; 170: 81–82
  • Cohen S. M. Cell proliferation in the bladder and implications for cancer risk assessment. Toxicology 1995a; 102: 149–159
  • Cohen S. M. Human relevance of animal carcinogenicity studies. Regulatory Toxicology and Pharmacology 1995b; 21: 75–80
  • Cohen S. M. Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicologic Pathology 2001; 183–190, 29 Suppl
  • Colagiuri S., Miller J. J., Edwards R. A. Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition 1989; 50: 474–478
  • Colson A., Lederer J., Michiels J. Ocular lesions induced by saccharin and its pollutants in the rat fetus. Journal Francais d'Ophtalmologie 1984; 7: 399–410, (in French)
  • Conceicao M. M., Fernandes V. J., Jr., Souza A. G., Nascimento T. G., Aragao C. F.S., Macedo R. O. Study of thermal degradation of aspartame and its products of conversion in sweetener using isothermal thermogravimetry and HPLC. Thermochimica Acta 2005; 433: 163–169
  • Cottrell G. T., Ferguson A. V. Sensory circumventricular organs: central roles in integrated autonomic regulation. Regulatory Peptides 2004; 117: 11–23
  • Coulombe R. A., Jr., Sharma R. P. Neurobiochemical alterations induced by the artificial sweetener aspartame (NutraSweet). Toxicology and Applied Pharmacology 1986; 83: 79–85
  • Creppy E. E., Baudrimont I., Marie A. How aspartame prevents the toxicity of ochratoxin A. Journal of Toxicological Sciences 1998; 23: 165–172
  • CSFII 1994–96. Continuing Survey of Food Intakes by Individuals (CSFII). 1994–96, 98. Agricultural Research Service, US Department of Agriculture, Washington, DC 2000, CD-ROM
  • Curtius H. C., Endres W., Blau N. Effect of high–protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria. Metabolism: Clinical and Experimental 1994; 43: 413–416
  • D'Amico M., Wu K., Di Vizio D., Reutens A. T., Stahl M., Fu M., Albanese C., Russell R. G., Muller W. J., White M., Negassa A., Lee H. W., DePinho R. A., Pestell R. G. The role of Ink4a/Arf in ErbB2 mammory gland tumorigenesis. Cancer Research 2003; 63: 3395–3402
  • da Silva L. C.S., Carvalho T. S., da Silva F. B., Pires R. F., Giugliani R., Pereira M. L.S. Aspartame loading test in PKU heterozygous individuals bearing severe and moderate mutations. Clinical Genetics. 2000; 58: 86–88
  • Dailey J. W., Lasley S. M., Burger R. L., Bettendorf A. F., Mishra P. K., Jobe P. C. Amino acids, monoamines and audiogenic seizures in genetically epilepsy-prone rats: Effects of aspartame. Epilepsy Research 1991; 8: 122–133
  • Dailey J. W., Lasley S. M., Mishra P. K., Bettendorf A. F., Burger R. L., Jobe P. C. Aspartame fails to facilitate pentylenetetrazol-induced convulsions in CD-1 mice. Toxicology and Applied Pharmacology 1989; 98: 475–486
  • de la Hunty A., Gibson S., Ashwell M. A review of the effectiveness of aspartame in helping weight control. Nutrition Bulletin 2006; 31: 115–128
  • Diomede L., Romano M., Guiso G., Caccia S., Nava S., Salmona M. Interspecies and interstrain studies on the increased susceptibility to metrazol-induced convulsions in animals given aspartame. Food and Chemical Toxicology 1991; 29: 101–106
  • Dow-Edwards D. L., Scribani L. A., Riley E. P. Impaired performance on odor-aversion testing following prenatal aspartame exposure in the guinea pig. Neurotoxicology and Teratology 1989; 11: 413–416
  • Drewnowski A., Massien C., Louis-Sylvestre J., Fricker J., Chapelot D., Apfelbaum M. The effects of aspartame versus sucrose on motivational ratings, taste preferences, and energy intakes in obese and lean women. International Journal of Obesity 1994; 18: 570–578
  • Durnev A. D., Oreshchenko A. V., Kulakova A. V., Beresten N. F., Seredenin S. B. Study into the clastogenic activity of dietary sugar substitutes. Voprosy Meditsinskoi Khimii 1995; 41: 31–33, (in Russian)
  • Easterby-Smith V., Besford J., Heath M. R. The effect of age on the recognition thresholds of three sweeteners: Sucrose, saccharin and aspartame. Gerodontology 1994; 11: 39–45
  • Eastin W. C., Mennear J. H., Tennant R. W., Stoll R. E., Branstetter D. G., Bucher J. R., McCullough B., Binder R. L., Spalding J. W., Mahler J. F. Tg.AC genetically altered mouse: assay working group overview of available data. Toxicologic Pathology 2001; 29: 60–80
  • EC. Aspartame. 2000, IUCLID Dataset. European Commission (EC). European Chemicals Bureau, CD-ROM
  • EC. Opinion of the Scientific Committee on Food: update on the safety of aspartame. 2002, (expressed on 4 December 2002). European Commission, Health and Consumer Protection Directorate-General, Brussels, Belgium. Report Number: SCF/CS/ADD/EDUL/222
  • Ecobichon D. J. Toxic effects of pesticides. Anticholinesterase agents. Casarett and Doull's Toxicology: The Basic Science of Poisons. 6th Edition, C. D. Klaassen. McGraw-Hill, New York 2001; 763, 774–784
  • EFSA. EFSA assesses new aspartame study and reconfirms its safety. European Food Safety Authority. European Ramazzini Foundation, BolognaItaly 2006
  • Ervin R. B., Wang C. Y., Wright M. P.H., Kennedy-Stephenson J. Dietary intake of selected minerals for the United States population: 1999–2000. Advance Data from Vital and Health Statistics. Centers for Disease Control and Prevention (CDC). 2004; 1–8, Report 341
  • FCC. Aspartame. Food Chemicals Codex. 5th Edition. National Academy Press, Washington, DC 2003; 37–38
  • FDA. Aspartame: Commissioner's final decision. Final Rule. Federal Registry 1981; 46: 38285–38307
  • FDA. 21 CFR part 172 Food additives permitted for direct addition to food for human consumption: aspartame: denial of request for hearing. United States Government Printing Office. Food and Drug Administration (FDA), Washington, DC 1984; 6672–6682, Final Rule. Vol. 49
  • FDA. Inactive Ingredients Database. Aspartame. US Food and Drug Administration. Center for Drug Evaluation and Research (CDER). 2006, http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (site visited on January 16, 2006)
  • Fernstrom J. D. Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note. Journal of Neural Transmission 1989; 75: 159–164
  • Fernstrom J. D. Dietary amino acids and brain function. Journal of the American Dietetic Association 1994; 94: 71–77
  • Fernstrom J. D., Fernstrom M. H., Gillis M. A. Acute effects of aspartame on large neutral amino acids and monoamines in rat brain. Life Sciences 1983; 32: 1651–1658
  • Fernstrom J. D., Fernstrom M. H., Grubb P. E. Effects of aspartame ingestion on the carbohydrate-induced rise in tryptophan hydroxylation rate in rat brain. American Journal of Clinical Nutrition 1986; 44: 195–205
  • Fernstrom J. D., Wurtman R. J., Hammarstrom-Wiklund B., Rand W. M., Munro H. N., Davidson C. S. Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. American Journal of Clinical Nutrition 1979; 32: 1912–1922
  • Filer L. J., Jr., Baker G. L., Stegink L. D. Effect of aspartame loading on plasma and erythrocyte free amino acid concentrations in one-year-old infants. Journal of Nutrition 1983; 113: 1591–1599
  • Filer L. J., Jr., Stegink L. D. Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects. Diabetes Care 1989; 12: 67–74
  • Finkelstein M. W., Daabees T. T., Stegink L. D., Applebaum A. E. Correlation of aspartate dose, plasma dicarboxylic amino acid concentration, and neuronal necrosis in infant mice. Toxicology 1983; 29: 109–119
  • Finkelstein M. W., Daabees T. T., Stegink L. D., Applebaum A. E. Aspartate-induced neuronal necrosis in infant mice: Protective effect of carbohydrate and insulin. Journal of Toxicology and Environmental Health 1988; 23: 395–406
  • Fisher R. S. Aspartame, neurotoxicity, and seizures: A review. Journal of Epilepsy 1989; 2: 55–64
  • Flamm W. G. Letter to the editor for “Increasing brain tumor rates: Is there a link to aspartame?”. Journal of Neuropathology and Experimental Neurology 1997; 56: 105–106
  • Fountain S. B., Hennes S. K., Teyler T. J. Aspartame exposure and in vitro hippocampal slice excitability and plasticity. Fundamental and Applied Toxicology 1988; 11: 221–228
  • Fountain S. B., Ting Y. L.T., Teyler T. J. The in vitro hippocampal slice preparation as a screen for neurotoxicity. Review paper. Toxicology In Vitro 1992; 6: 77–87
  • Francot P., Geoffroy P. Le methanol dans les jus de fruits, les boissons, fermentees, les alcools et spiritueux. Revue des Fermentations et des Industries Alimentaires 1956; 11: 279–287
  • Franz M. Is it safe to consume aspartame during pregnancy? A review. Nutrition update. Diabetes Educator 1986; 12: 145–147
  • French J., Storer R. D., Donehower L. A. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicologic Pathology 2001; 29: 24–29
  • Frenkel C., Peters J. S., Tieman D. M., Tiznado M. E., Handa A. K. Pectin methylesterase regulates methanol and ethanol accumulation in ripening tomato (Lycopersicon esculentum). fruit. Journal of Biological Chemistry 1998; 273: 4293–4295
  • Frey G. H. Use of aspartame by apparently healthy children and adolescents. Journal of Toxicology and Environmental Health 1976; 2: 401–415
  • Fry J. The world market for intense sweeteners. World Review of Nutrition and Dietetics 1999; 85: 211
  • FSA. List of current European Union-approved additives and their E numbers. Food Standards Agency (FSA), Aspartame 2002, www.foodstandards.gov.uk/safereating/additivesbranch/enumberlist (site visited on January 16, 2006)
  • FSANZ. Consumption of intense sweeteners in Australia and New Zealand: benchmark survey 2003. Food Standards Australia New Zealand. Report Series 8, Ray Morgan Research. 2004; 60, 62–63; 66–67; 87
  • Furda I., Malizia P. D., Kolor M. G., Vernieri P. J. Decomposition products of L-aspartyl-L-phenylalanine methyl ester and their identification by gas–liquid chromatography. Journal of Agricultureal and Food Chemistry 1975; 23: 340–343
  • Galvano F., Piva A., Ritieni A., Galvano G. Dietary strategies to counteract the effects of mycotoxins: A review. Journal of Food Protection 2001; 64: 120–131
  • Garbow J. R., Likos J. J., Schroeder S. A. Structure, dynamics, and stability of beta-cyclodextrin inclusion complexes of aspartame and neotame. Journal of Agricultural and Food Chemistry 2001; 49: 2053–2060
  • Garnier-Sagne I., Leblanc J. C., Verger P. Calculation of the intake of three intense sweeteners in young insulin-dependent diabetics. Food and Chemical Toxicology 2001; 39: 745–749
  • Garriga M. M., Berkebile C., Metcalfe D. D. A combined single-blind, double-blind, placebo-controlled study to determine the reproducibility of hypersensitivity reactions to aspartame. Journal of Allergy and Clinical Immunology 1991; 87: 821–827
  • Gautschi M., Schmid J. P. Chemical characterization of diketopiperazines in beer. Journal of Agricultural and Food Chemistry 1997; 45: 3183–3189
  • Gebara J. S., Querol C. B., Gebara M., Castro-Prado M. A.A. Mitotic segregation induced by edulcorant l-aspartyl-l-phenylalanine-methyl-ester (aspartame). in diploid cells of Aspergillus nidulans. Acta Scientiarum Biological Sciences 2003; 25: 203–206
  • Geha R. Aspartame-induced lobular panniculitis. Journal of the American Academy of Dermatology 1992; 26: 277–278
  • Geha R., Buckley C. E., III, Greenberger P., Patterson R., Polmar S., Saxon A., Rohr A., Yang W., Drouin M. Aspartame is no more likely than placebo to cause urticaria/angioedema: Results of a multicenter, randomized, double-blind, placebo-controlled, crossover study. Journal of Allergy and Clinical Immunology 1993; 92: 513–520
  • Gibbs B. F., Alli I., Mulligan C. N. Simple and rapid high-performance liquid chromatographic method for the determination of aspartame and its metabolites in foods. Journal of Chromatography A 1996; 725: 372–377
  • Giknis M. L.A., Clifford C. B. Compilation of spontaneous neoplastic lesions and survival in Crl:CD® (SD). rats from control groups. Charles River Laboratories Inc., Wilmington, MA 2004
  • Ginz M., Engelhardt U. H. Identification of proline-based diketopiperazines in roasted coffee. Journal of Agricultural and Food Chemistry 2000; 48: 3528–3532
  • Goerss A. L., Wagner G. C., Hill W. L. Acute effects of aspartame on aggression and neurochemistry of rats. Life Sciences 2000; 67: 1325–1329
  • Goodman J. I. A perspective on current and future uses of alternative models for carcinogenicity testing. Toxicologic Pathology 2001; 29: 173–176
  • Gougeon R., Spidel M., Lee K., Field C. J. Canadian diabetes association national nutrition committee technical review: Non-nutritive intense sweeteners in diabetes management. Canadian Journal of Diabetes 2004; 28: 385–399
  • Groff J. L., Gropper S. S. Nutrition and the central nervous system. Advanced Nutrition and Human Metabolism. 3rd Edition. Wadsworth Thompson Learning, Belmont, CA 2000; 536–551
  • Guiso G., Caccia S., Vezzani A., Stasi M. A., Salmona M., Romano M., Garattini S. Effect of aspartame on seizures in various models of experimental epilepsy. Toxicology and Applied Pharmacology 1988; 96: 485–493
  • Guiso G., Diomede L., Romano M., Caccia S., Sarati S., Salmona M. Effect of tyrosine on the potentiation by aspartame and phenylalanine of metrazol-induced convulsions in rats. Food and Chemical Toxicology 1991; 29: 855–857
  • Gulya A. J., Sessions R. B., Troost T. R. Aspartame and dizziness: Preliminary results of a prospective, nonblinded, prevalence and attempted cross-over study. American Journal of Otology 1992; 13: 438–442
  • Gupta V., Cochran C., Parker T. F., Long D. L., Ashby J., Gorman M. A., Liepa G. U. Effect of aspartame on plasma amino acid profiles of diabetic patients with chronic renal failure. American Journal of Clinical Nutrition 1989; 49: 1302–1306
  • Gurney J. G., Podgoda J. M., Holly E. A., Hectht S. S., Preston-Martin S. Aspartame consumption in relation to childhood brain tumor risk: Results from a case-control study. Journal of the National Cancer Institute 1997; 89: 1072–1074
  • Hagiwara A., Fukushima S., Kitaori M., Shibata M., Ito N. Effects of three sweeteners on rat urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Gann 1984; 75: 763–768
  • Hallert C., Martensson J., Allgen L. G. Brain availability of monoamine precursors in adult coeliac disease. Scandinavian Journal of Gastroenterology 1982; 17: 87–89
  • Hantson P., Haufroid V., Wallemacq P. Formate kinetics in methanol poisoning. Human & Experimantal Toxicology 2005; 24: 55–59
  • Hardell L., Mild K. H., Pahlson A., Hallquist A. Ionizing radiation, cellular telephones and the risk for brain tumours. European Journal of Cancer Prevention 2001; 10: 523–529
  • Hauptmann M., Lubin J. H., Stewart P. A., Hayes R. B., Blair A. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries. Journal of the National Cancer Institute 2003; 95: 1615–1623
  • Hauptmann M., Lubin J. H., Stewart P. A., Hayes R. B., Blair A. Mortality from solid cancers among workers in formaldehyde industries. American Journal of Epidemiology 2004; 159: 1117–1130
  • Health Canada. Aspartame. Health Canada. 2005, http://www.hc-sc.gc.ca/fn-an/securit/facts-faits/aspartame/aspartame01_e.html (site visited on October 26, 2006)
  • Helali N. Y., El Kashef H., Salem H., Gamiel N., Elmazar M. M.A. The effect of aspartame on seizure susceptibility and the anticonvulsant action of ethosuximde, valproate and phenytoin in mice. Saudi Pharmaceutical Journal 1996; 4: 149–156
  • Hellier M. D., Radhakrishnan A. N., Ganapathy V., Mathan V. I., Baker S. J. Intestinal perfusion studies in tropical sprue. 1. Amino acid and dipeptide absorption. Gut 1976; 17: 511–516
  • Heybach J. P., Ross C. Aspartame consumption in a representative sample of Canadians. Journal of the Canadian Dietetic Association 1989; 50: 166–170, (cited in Butchko et al., 1991)
  • Hilton C. W., Prasad C., Vo P., Mouton C. Food contains the bioactive peptide, Cyclo (His-Pro)*. Journal of Clinical Endocrinology and Metabolism 1992; 75: 375–378
  • Hinson A. L., Nicol W. M. Monitoring sweetener consumption in Great Britain. Food Additives and Contaminants 1992; 9: 669–680
  • Hjelle J. J., Dudley R. E., Marietta M. P., Sanders P. G., Dickie B. C., Brisson J., Kotsonis F. N. Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. Pharmacology 1992; 44: 48–60
  • Holder M. D. Effects of perinatal exposure to aspartame on rat pups. Neurotoxicology and Teratology 1989; 11: 1–6
  • Holder M. D., Yirmiya R. Behavioral assessment of the toxicity of aspartame. Pharmacology, Biochemistry & Behavior 1989; 32: 17–26
  • Homler B. E. Aspartame: Implications for the food scientist. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 247–262
  • Hooper N. M., Hesp R. J., Tieku S. Metabolism of aspartame by human and pig intestinal microvillar peptidases. Biochemical Journal 1994; 298: 635–639
  • Horwitz D. L., McLane M., Kobe P. Response to single dose of aspartame or saccharin by NIDDM patients. Diabetes Care 1988; 11: 230–234
  • Hursting S. D., Lavigne J. A., Berrigan D., Donehower L. A., Davis B. J., Phang J. M., Barrett J. C., Perkins S. N. Diet–gene interactions in p53-deficient mice: Insulin-like growth factor-1 as a mechanistic target. Journal of Nutrition 2004; 134: 2482S–2486S
  • Ilback N. G., Alzin M., Jahrl S., Enghardt-Barbieri H., Busk L. Estimated intake of the artificial sweeteners acesulfame-K, aspartame, cyclamate and saccharin in a group of Swedish diabetics. Food Additives and Contaminants 2003; 20: 99–114
  • Imbus H. R. A review of regulatory risk assessment with formaldehyde as an example. Regulatory Toxicology and Pharmacology 1988; 8: 356–366
  • Innes J. R.M., Garner F. M., Stokey J. L. Respiratory disease in rats. Pathology of Laboratory Rats and Mice, E. Cotchin, J. F. C. Roe. Blackwell Scientific Publications, Oxford 1967; 229–257
  • Institute of Medicine. Protein and amino acids. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. National Academies Press, Washington, DC 2005; 701–703; 727–728
  • Ishii H. Incidence of brain tumors in rats fed aspartame. Toxicology Letters 1981; 7: 433–437
  • Ishii H., Koshimizu T., Usami S., Fujimoto T. Toxicity of aspartame and its diketopiperazine for Wistar rats by dietary administration for 104 weeks. Toxicology 1981; 21: 91–94
  • Ito N., Fukushima S., Shirai T., Nakanishi K. Effects of promoters on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in the rat. Environmental Health Perspectives 1983; 50: 61–69
  • Jacobson-Kram D., Sistare F. D., Jacobs A. C. Use of transgenic mice in carcinogenicity hazard assessment. Toxicologic Pathology 2004; 32: 49–52
  • JECFA. Aspartame. World Health Organization, Geneva 1980a, Toxicological Evaluation of Certain Food Additives and Contaminants. World Health Organization Technical Report Series No. 653. Prepared by the Twenty-third Report of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Food Additive Series 15.
  • JECFA. Diketopiperazine. Evaluation of Certain Food Additives. WHO Technical Report Series No. 653, World Health Organization, Geneva 1980b; 20–21, Twenty-fourth Report of the Joint FAO/WHO Expert Committee on Food Additives (JECFA)
  • JECFA. Compendium of food additive specifications. World Health Organization (WHO). and Food and Agriculture Organization of the United Nations (FAO), Rome 1992; 161–166, FAO Food and Nutrition paper 52. Addendum 1. Aspartame. In Joint FAO/WHO Expert Committee on Food Additives (JECFA). Combined Specifications from the 1st to the 37th Meeting in Rome 1956–1990.
  • JECFA. Summary of evaluations performed by the Joint FAO/WHO Expert Committee on Food Additives. Aspartame. World Health Organization. 2003, http://jecfa.ilsi.org/evaluation.cfm?chemical=ASPARTAME&keyword=ASPARTAME (site visited on January 16, 2006)
  • Jeffrey A. M., Iatropoulos M. J., Williams G. M. Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals. Toxicologic Pathology 2006; 34: 827–852
  • Jeffrey A. M., Williams G. M. Lack of DNA-damaging activity of five nonnutritive sweeteners in the rat hepatocyte/DNA repair assay. Food and Chemical Toxicology 2000; 38: 335–338
  • JFCRF. Seventh Edition Japan's specifications and standards for food additives. Aspartame. Standards for use, according to use categories. The Ministry of Health and Welfare, TokyoJapan 2000, The Japan Food Chemical Research Foundation (JFCRF). English translation
  • Jobe P. C., Dailey J. W. Aspartame and seizures. Review articles. Amino Acids 1993; 4: 197–235
  • Johns D. R. Aspartame and headache. Dietary Phenylalanine and Brain Function, R. J. Wurtman, E. Ritter-Walker. Birkhäuser, Boston 1988; 303–312
  • Jonker D., Til H. P., Falke H. E., Dreef-van der Meulen H. C. Sub-chronic (90-day). oral toxicity with aspartame in rats. Zeist, The Netherlands 1987, Final Report. TNO Division for Nutrition and Food Research, Report V87.110/260689
  • Kai K., Sahto H., Yoshida M., Suzuki T., Shikanai Y., Kajimura T., Furuhama K. Species and sex differences in susceptibility to olfactory lesions among the mouse, rat and monkey following an intravenous injection of vincristine sulphate. Toxicologic Pathology 2006; 34: 223–231
  • Karim A., Burns T. Metabolism and pharmacokinetics of radiolabeled aspartame in normal subjects. The Clinical Evaluation of a Food Additive: Assessment of Aspartame, C. Tschanz, H. H. Butchko, W. W. Stargel, F. N. Kotsonis. CRC Press, Boca Raton, FL 1996; 57–66
  • Karstaedt P. J., Pincus J. H. Aspartame use in Parkinson's disease. Neurology 1993; 43: 611–613
  • Kerns W., II, Tomaszewski C., McMartin K., Ford M., Brent J., the META Study Group. Formate kinetics in methanol poisoning. Clinical Toxicology 2002; 40: 137–143
  • Knudson A. G., Jr., Hethcote H. W., Brown B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America 1975; 72: 5116–5120
  • Knudson A. G. Hereditary cancer: Two hits revisited. Journal of Cancer Research and Clinical Oncology 1996; 122: 135–140
  • Koch R., Schaeffler G., Shaw K. N.F. Results of loading doses of aspartame by two phenylketonuric (PKU). children compared with two normal children. Journal of Toxicology and Environmental Health 1976a; 2: 459–469
  • Koch R., Shaw K. N.F., Williamson M., Haber M. Use of aspartame in phenylketonuric heteroxygous adults. Journal of Toxicology and Environmental Health 1976b; 2: 453–457
  • Koehler S. M., Glaros A. The effect of aspartame on migraine headache. Headache 1988; 28: 10–14
  • Koeppe R. A., Shulkin B. L., Rosenspire K. C., Shaw L. A., Betz A. L., Mangner T., Price J. C., Agranoff B. W. Effect of aspartame-derived phenylalanine on neutral amino acid uptake in human brain: a positron emission tomography study. Journal of Neurochemistry 1991; 56: 1526–1535
  • Koestner A. Aspartame and brain tumors: Pathology issues. Aspartame Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 447–457
  • Koestner A. Letter to the editor for “Increasing brain tumor rates: Is there a link to aspartame?”. Journal of Neuropathology and Experimental Neurology 1997; 56: 107–109
  • Kostic M. A., Dart R. C. Rethinking the toxic methanol level. Review. Journal of Toxicology. Clinical Toxicology 2003; 41: 793–800
  • Kotsonis F. N., Hjelle J. J. The safety assessment of aspartame: Scientific and regulatory considerations. The Clinical Evaluation of a Food Aditive Assessment of Aspartame, C. Tschanz, H. H. Butchko, W. W. Stargel, F. N. Kotsonis. CRC Press, Boca Raton, FL 1996; 23–41
  • Kovatsi L., Tsouggas M. The effect of oral aspartame administration on the balance of magnesium in the rat. Magnesium Research 2001; 14: 189–194
  • Kovatsi L., Tsouggas M. The effect of oral aspartame administration on the excretion and distribution of zinc in rat tissues. Trace Elements and Electrolytes 2002; 19: 11–14
  • Krohn J. A. Aspartame and attention deficit disorder (ADD). Pediatrics 1994; 94: 576
  • Kruesi M. J.P., Rapoport J. L., Cummings E. M., Berg C. J., Ismond D. R., Flament M., Yarrow M., Zahn-Waxler C. Effects of sugar and aspartame on aggression and activity in children. American Journal of Psychiatry 1987; 144: 1487–1490
  • Kulczycki A., Jr. Aspartame-induced urticaria. Brief reports. Annals of Internal Medicine 1986; 104: 207–208
  • Kulczycki A., Jr. Aspartame-induced hives. Correspondence. Journal of Allergy and Clinical Immunology 1995; 95: 639–640
  • Kumar A., Rawlings R. D., Beaman D. C. The mystery ingredients: sweeteners, flavorings, dyes, and preservatives in analgesic/antipyretic, antihistamine/decongestant, cough and cold, antidiarrheal, and liquid theophylline preparations. Pediatrics 1993; 91: 927–933
  • LaBuda C. J., Fuchs P. N. A comparison of chronic aspartame exposure to aspirin on inflammation, hyperalgesia and open field activity following carrageenan-induced monoarthritis. Life Sciences 2001; 69: 443–454
  • LaBuda C. J., Hale R. L. Anxiety in mice following acute aspartame and ethanol exposure. Alcohol 2000; 20: 69–74
  • Lajtha A., Reilly M. A., Dunlop D. S. Aspartame consumption: Lack of effects on neural function. Journal of Nutritional Biochemistry 1994; 5: 266–283
  • Lapierre K. A., Greenblatt D. J., Goddard J. E., Harmatz J. S., Shader R. I. The neuropsychiatric effects of aspartame in normal volunteers. Journal of Clinical Pharmacology 1990; 30: 454–460
  • Larsen J. C., Richold M. Report of workshop on the significance of excursions of intake above the ADI. Regulatory Toxicology and Pharmacology 1999; 30: S2–12
  • Lau K., McLean W. G., Williams D. P., Howard C. V. Synergistic interactions between commonly used food additives in a developmental neurotoxicity test. Toxicological Sciences 2005; 90: 178–187
  • Leclercq C., Arcella D., Le Donne C., Piccinelli R., Sette S., Soggiu M. E. Stochastic modelling of human exposure to food chemicals and nutrients within the "Montecarlo" project: an exploration of the influence of brand loyalty and market share on intake estimates of intense sweeteners from sugar-free soft drinks. Toxicology Letters 2003; 140–141: 443–457
  • Leclercq C., Berardi D., Sorbillo M. R., Lambe J. Intake of saccharin, aspartame, acesulfame K and cyclamate in Italian teenagers: Present levels and projections. Food Additives and Contaminants 1999; 16: 99–109
  • Lederer J., Bodin J., Colson A. Aspartame and its effect on gestation in rats. Journal de Toxicologie Clinique et Experimentale 1985; 5: 7–14, (in French)
  • Legler J. M., Ries L. A.G., Smith M. A., Warren J. L., Heineman E. F., Kaplan R. S., Linet M. S. Brain and other central nervous system cancers: Recent trends in incidence and mortality. Journal of the National Cancer Institute 1999; 91: 1382–1390
  • Lennon H. D., Metcalf L. E., Mares S. E., Smith J. H., Nutting E. F., Saunders F. J. The biological properties of aspartame. IV. Effects on reproduction and lactation. Journal of Environmental Pathology and Toxicology 1980; 3: 375–386
  • Leon A. S. Comment on effect of large doses of aspartame on urinary calcium excretion. Journal of Clinical Endocrinology and Metabolism 1999; 84: 382–384
  • Leon A. S., Hunninghake D. B., Bell C., Rassin D. K., Tephly T. R. Safety of long-term large doses of aspartame. Archives of Internal Medicine 1989; 149: 2318–2324
  • Levy P. S., Hedeker D. Letter to the editor. Statistical and epidemiological treatment of the SEER incidence data. Journal of Neuropathology and Experimental Neurology 1996; 55: 1280
  • Lim U., Subar A. F., Mouw T., Hartge P., Morton L. M., Stolzenberg-Solomon R., Campbell D. S., Hollenbeck A. R., Schechter A. Prospective study of aspartame-containing beverages and risk of hematopoietic and brain cancers. April 1, 2006. American Association for Cancer Research (AACR), Philadelphia, PH 2006a
  • Lim U., Subar A. F., Mouw T., Hartge P., Morton L. M., Stolzenberg-Solomon R., Campbell D., Hollenbeck A. R., Schatzkin A. Consumption of aspartame-containing beverages and incidence of hematopoietic and brain malignancies. Cancer Epidemiology Biomarkers & Prevention 2006b; 15: 1654–1659
  • Lindsey J. R., Davidson M. K., Schoeb T. R., Cassell G. H. Mycoplasma pulmonis-host relationships in a breeding colony of Sprague-Dawley rats with enzootic murine respiratory mycoplasmosis. Laboratory Animal Science 1985; 35: 597–608
  • Lipton R. B., Newman L. C., Cohen J. S., Solomon S. Aspartame as a dietary trigger of headache. Headache 1989; 29: 90–92
  • Lipton W. E., Li Y. N., Younoszai M. K., Stegink L. D. Intestinal absorption of aspartame decomposition products in adult rats. Metabolism 1991; 40: 1337–1345
  • Lubet R., Wang Y., Zhang Z., You M. Mouse models incorporating alterations in the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapetutic agents. Experimental Lung Research 2005; 31: 117–133
  • MacDonald J., French J. E., Gerson R. J., Goodman J., Inoue T., Jacobs A., Kasper P., Keller D., Lavin A., Long G., McCullough B., Sistare F. D., Stoter R., Willem van der Laan J. The utility of genetically modified mouse assays for identifiying human carcinogens: a basic understanding and path forward. Toxicological Sciences 2004; 77: 188–194
  • Maher T. J., Wurtman R. J. High doses of aspartame reduce blood pressure in spontaneously hypertensive rats. New England Journal of Medicine 1983; 309: 1125
  • Malaisse W. J., Vanonderbergen A., Louchami K., Jijakli H., Malaisse-Lagae F. Effects of artificial sweeteners on insulin release and cationic fluxes in rat pancreatic islets. Cell Signal 1998; 10: 727–733
  • Marsh G. M., Youk A. O. Reevaluation of mortality risks from leukemia in the formaldehyde cohort study of the National Cancer Institute. Regulatory Toxicology and Pharmacology 2004; 40: 113–124
  • Marsh G. M., Youk A. O. Reevaluation of mortality risks from nasopharyngeal cancer in the formaldehyde cohort study of the National Cancer Institute. Regulatory Toxicology and Pharmacology 2005; 42: 275–283
  • Marsh G. M., Youk A. O., Buchanich J. M., Cassidy L. D., Lucas L. J., Esmen N. A., Gathuru I. M. Pharyngeal cancer mortality among chemical plant workers exposed to formaldehyde. Toxicology and Industrial Health 2002; 18: 257–268
  • Marsh G. M., Youk A. O., Collins J. J. Reevaluation of lung cancer risk in the acrylonitrile cohort study of the National Cancer Institute and the National Institute for Occupational Safety and Health. Scandinavian Journal of Work, Environment and Health 2001; 27: 5–13
  • Marsh G. M., Youk A. O., Morfeld P. Mis-specified and nonrobust mortality risk models for nasopharyngeal cancer in the National Cancer Institute formaldehyde worker cohort study. Regulatory Toxicology and Pharmacology 2006; 47: 59–67
  • Marsh G. M., Youk A. O., Buchanich J. M., Erdal S., Esmen N. A. Work in the metal industry and nasopharyngeal cancer mortality among formaldehyde-exposed workers. Regulatory Toxicology and Pharmacology 2007; 48: 308–319
  • Matthews D. M. Absorption of peptides, amino acids, and their methylated derivatives. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 29–46
  • Mazur R. H. Discovery of aspartame. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 3–9
  • McCauliffe D. P., Poitras K. Aspartame-induced lobular panniculitis. Journal of the American Academy of Dermatology 1991; 24: 298–300
  • McConnell R. G. G.D. Searle & Co., Skokie, Illinois 1973, SC-18862 (Aspartame): A suplemental study of rat brains from two tumorigenicity studies (P-T Nos. 838H71 and 892H72). E-87. Searle Laboratories, Inc., Report 1227
  • Meldrum B. Amino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders. Brain Research Reviews 1993; 18: 293–314
  • Meldrum B. S., Nanji N., Cornell R. G. Lack of effect of aspartame or of L-phenylalanine on photically induced myoclonus in the baboon, Papio papio. Epilepsy Research 1989; 4: 1–7
  • Merriam Webster. Clonus. 2006a, http://www.m-w.com/dictionary/clonic (site visited on October 10, 2006a)
  • Merriam Webster. Tonic. 2006b, http://www.m-w.com/dictionary/tonic (site visited on October 10, 2006b)
  • Mishra D. N., Bindal M., Singh S. K., Kumar S. G.V. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. Chemical and Pharmaceutical Bulletin 2006; 54: 99–102
  • MMWR. Evaluation of consumer complaints related to aspartame use. Morbidity and Mortality Weekly Report 1984; 33: 605–607
  • Mojet J., Heidema J., Christ-Hazelhof E. Taste perception with age: Generic or specific losses in supra-threshold intensities of five taste qualities?. Chemical Senses 2003; 28: 397–413
  • Molinary S. V. SC-18862: An evaluation of mutagenic potentialy employing the Ames Salmonella/microsome assay. G.D. Searle & Co., Skokie, Illinois 1978
  • Morin C. L., Roy C. C., Lasalle R., Bonin A. Small bowel mucosal dysfunction in patients with cystic fibrosis. Journal of Pediatrics 1976; 88: 213–216
  • Mukhopadhyay M., Mukherjee A., Chakrabarti J. In vivo cytogenetic studies on blends of aspartame and acesulfame-K. Food and Chemical Toxicology 2000; 38: 75–77
  • Mullenix P. J., Tassinari M. S., Schunior A., Kernan W. J. No change in spontaneous behavior of rats after acute oral doses of aspartame, phenylalanine, and tyrosine. Fundamental and Applied Toxicology 1991; 16: 495–505
  • Nakao H., Umebayashi C., Nakata M., Nishizaki Y., Noda K., Okano Y., Oyama Y. Formaldehyde-induced shrinkage of rat thymocytes. Journal of Pharmacological Sciences 2003; 91: 83–86
  • National Research Council. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC 2006, http://www.nap.edu/readingroom/books/labrats/chaps.html#anim (site visited on January 19, 2006)
  • Nehrling J. K., Kobe P., McLane M. P., Olson R. E., Kamath S., Horwitz D. L. Aspartame use by persons with diabetes. Diabetes Care 1985; 8: 415–417
  • Nelson J. B. Respiratory infections of rats and mice with emphasis on indigenous mycoplasms. Pathology of Laboratory Rats and Mice, E. Cotchin, J. F. C. Roe. Blackwell Scientific Publications, Oxford 1967; 259–294
  • Newman L. C., Lipton R. B. Migraine MLT-down: An unusual presentation of migraine in patients with aspartame-triggered headaches. Case report. Headache 2001; 41: 899–901
  • Nguyen U. N., Dumoulin G., Henriet M. T., Regnard J. Aspartame ingestion increases urinary calcium, but not oxalate excretion, in healthy subjects. Journal of Clinical Endocrinology and Metabolism 1998; 83: 165–168
  • NLM and NIH. Medlineplus medical encylopedia: Plasma amino acids. US National Library of Medicine (NLM). and the National Institute of Health (NIH). 2005, http://www.nlm.nih.gov/medlineplus/ency/article/003361.htm (site visited on March 15, 2006)
  • NTP. Overview of transgenic mouse models. National Toxicology Program (NTP), NIEHS, NIH, Research Triangle Park, NC 2001
  • NTP. 2005; 1–224, NTP report on the toxicology studies of aspartame in genetically modified (FVB Tg.AC hemizygous). and B6.129-Cdkn2a (N2). deficient mice and carcinogenicity studies of aspartame in genetically modified [B6.129 Trp53tm1Brd(N5). haploinsufficient] mice (feed studies). National Toxicology Program (NTP), Research Triangle Park, NC. Report 06-4459,
  • Nutzenadel W., Fahr K., Lutz P. Absorption of free and peptide-linked glycine and phenylalanine in children with active celiac disease. Pediatric Research 1981; 15: 309–312
  • O'Kane R. L., Martinez-Lopez I., DeJoseph M. R., Vina J. R., Hawkins R. A. Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3). of the blood–brain barrier. A mechanism for glutamate removal. Journal of Biological Chemistry 1999; 274: 31891–31895
  • OECD. OECD guidelines for testing of chemicals No.451 Carcinogenicity Studies, adopted May 12, 1981. Organisation for Economic and Co-Operation Development (OECD), ParisFrance 1981, Report 451
  • Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P. L., Burkhard C., Schuler D., Probst-Hensch N. M., Maiorka P. C., Baeza N., Pisani P., Yonekawa Y., Yasargil M. G., Lutolf U. M., Kleihues P. Genetic pathways to glioblastoma: A population-based study. Cancer Research 2004; 64: 6892–6899
  • Okaniwa A., Hori M., Masuda M., Takeshita M., Hayashi N., Wada I., Doi K., Ohara Y. Histopathological study on effects of potassium aspartate on the hypothalamus of rats. Journal of Toxicological Sciences 1979; 4: 31–45
  • Okubo T., Kano I. Studies on estrogenic activities of food additives with human breast cancer MCF-7 cells and mechanism of estrogenicity by BHA and OPP. Yakugaku Zasshi 2003; 123: 443–452, (in Japanese)
  • Olney J. W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969; 164: 719–721
  • Olney J. W. Excitatory neurotoxins as food additives: An evaluation of risk. Neurotoxicology 1980; 2: 163–192
  • Olney J. W., Farber N. B., Spitznagel E., Robins L. N. Increasing brain tumor rates: is there a link to aspartame?. Journal of Neuropathology and Experimental Neurology 1996; 55: 1115–1123
  • Olney J. W., Ho O. L. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970; 5258: 609–611
  • Olney J. W., Sharpe L. G. Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969; 166: 386–388
  • Oppermann J. A., Muldoon E., Ranney R. E. Effect of aspartame on phenylalanine metabolism in the monkey. Journal of Nutrition 1973a; 103: 1460–1466
  • Oppermann J. A., Muldoon E., Ranney R. E. Metabolism of aspartame in monkeys. Journal of Nutrition 1973b; 103: 1454–1459
  • Oppermann J. A., Ranney R. E. The metabolism of aspartate in infant and adult mice. Journal of Environmental Pathology and Toxicology 1979; 2: 987–998
  • Osfor M. M.H., Elias T. R. Nutritional and biochemical studies on some artificial sweeteners administered to male albino rats. Bulletin of the National Research Centre (Cairo) 2003; 28: 377–401
  • Owen B. A., Dudney C. S., Tan E. L., Easterly C. E. Formaldehyde in drinking water: comparative hazard evaluation and an approach to regulation. Regulatory Toxicology and Pharmacology 1990; 11: 220–236
  • PAFA. Priority-Based Assessment of Food Additives (PAFA). Center for Food Safety and Applied Nutrition (CFSAN). U.S. Food and Drug Administration, Washington, DC 1993; 1–3; 10–21; 29–34; 45–46; 58
  • Paine A., Dayan A. D. Defining a tolerable concentration of methanol in alcoholic drinks. Human and Experimental Toxicology 2001; 20: 563–568
  • Pardridge W. M. Blood–brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochemical Research 1998; 23: 635–644
  • Pattanaargson S., Chuapradit C., Srisukphonraruk S. Aspartame degradation in solutions at various pH conditions. Food Chemistry and Toxicology 2001; 66: 808–809
  • Pattanaargson S., Sanchavanakit C. Aspartame degradation study using electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry RCM 2000; 14: 987–993
  • Pettit S. D. Panel discussion on the application of alternative models to cancer risk assessment. Toxicologic Pathology 2001; 29: 191–195
  • Pinto J. M.B., Maher T. J. Administration of aspartame potentiates pentylenetetrazole- and fluorothyl-induced seizures in mice. Neuropharmacology 1988a; 27: 51–55
  • Pinto J. M.B., Maher T. J. Aspartame, phenylalanine, and seizures in experimental animals. Dietary Phenylalanine and Brain Function, R. J. Wurtman, E. Ritter-Walker. Birkhauser, Boston 1988b; 95–103
  • Pivonka E. E., Grunewald K. K. Aspartame- or sugar-sweetened beverages: Effects on mood in young women. Journal of the American Dietetic Association 1990; 90: 250–254
  • Pizzi W. J., Tabor J. M., Barnhart J. E. Somatic, behavioral, and reproductive disturbances in mice following neonatal administration of sodium L-aspartate. Pharmacology, Biochemistry, and Behavior 1978; 9: 481–485
  • Popp J. A. Criteria for the evaluation of studies in transgenic models. Toxicologic Pathology 2001; 29: 20–23
  • Potts W. J. Behavioral effects of chronic feeding L-phenylalanine and SC-18862 to weaning rats. Searle Laboratories, Inc., Chicago 1972, Report PT 849570
  • Potts W. J., Bloss J. L., Nutting E. F. Biological properties of aspartame. I. Evaluation of central nervous system effects. Journal of Environmental Pathology and Toxicology 1980; 3: 341–353
  • Pritchard J. B., French J. E., Davis B. J., Haseman J. K. The role of transgenic mouse models in carcinogen identification. Research articles. Environmental Health Perspectives 2003; 111: 444–454
  • Prodolliet J., Bruelhart M. Determination of aspartame and its major decomposition products in foods. Journal of AOAC International 1993; 76: 275–282
  • Prudel M., Davidkova E., Davidek J., Kminek M. Kinetics of decomposition of aspartame hydrochloride (Usal). in aqueous solutions. Journal of Food Science 1986; 51: 1393–1397; 1415
  • Quinlan M., Mialon V., Everitt M. Effect of storage on the flavours of cola drinks sweetened with different sweetener systems. World Review of Nutrition and Dietetics 1999; 85: 58–63
  • Ranney R. E., Mares S. E., Schroeder R. E., Hutsell T. C., Raczialowski F. M. The phenylalanine and tyrosine contnet of maternal and fetal body fluids from rabbits fed aspartame. Toxicology and Applied Pharmacology 1975; 32: 339–346
  • Ranney R. E., Oppermann J. A. A review of the metabolism of the aspartyl moiety of aspartame in experimental animals and man. Journal of Environmental Pathology and Toxicology 1979; 2: 979–985
  • Ranney R. E., Oppermann J. A., Muldoon E., McMahon F. G. Comparative metabolism of aspartame in experimental animals and humans. Journal of Toxicology and Environmental Health 1976; 2: 441–451
  • Rao K. S., Mauro J., McConnell R. G. E-27. SC-18862: 46 Week oral toxicity study in the hamster. G. S. Searle & Co. to FDA. Searle Laboratories, Chicago 1972a
  • Rao K. S., Mauro J., McConnell R. G. E-28. SC-18862: 106 Week oral toxicity study in the dog. G. S. Searle & Co. to FDA. Searle Laboratories, Chicago 1972b
  • Rao K. S., Stejskal R., McConnell R. G. E-77 & E-78. SC-19192: 115 Week tumorigenicity study in the rat. G. S. Searle & Co. to FDA. Searle Laboratories, Chicago 1974
  • Reilly M. A., Debler E. A., Fleischer A., Lajtha A. Chronic aspartame ingestion does not alter cerebral levels of aminergic neurotransmitters and related amino acids in the rat brain. Research Communications in Psychology, Psychiatry and Behavior 1989a; 14: 287–303
  • Reilly M. A., Debler E. A., Fleischer A., Lajtha A. Lack of effect of chronic aspartame ingestion on aminergic receptors in rat brain. Biochemical Pharmacology 1989b; 38: 4339–4341
  • Reilly M. A., Debler E. A., Lajtha A. Perinatal exposure to aspartame does not alter aminergic neurotransmitter systems in weanling rat brain. Research Communications in Psychology, Psychiatry and Behavior 1990; 15: 141–159
  • Reilly M. A., Lajtha A. Glutamatergic receptor kinetics are not altered by perinatal exposure to aspartame. Neurochemistry International 1995; 26: 217–222
  • Rencuzogullari E., Tuylu B. A., Topaktas M., Ila H. B., Kayraldiz A., Arslan M., Diler S. B. Genotoxicity of aspartame. Drug and Chemical Toxicology 2004; 27: 257–268
  • Renwick A. G. The metabolism of intense sweeteners. Xenobiotica 1986; 16: 1057–1071
  • Renwick A. G. Acceptable daily intake and the regulation of intense sweeteners. Food Additives and Contaminants 1990; 7: 463–475
  • Renwick A. G. The intake of intense sweeteners—An update review. Food Additives and Contaminants 2006; 4: 327–338
  • Reynolds W. A., Butler V., Lemkey-Johnston N. Hypothalamic morphology following ingestion of aspartame or MSG in the neonatal rodent and primate: A preliminary report. Journal of Toxicology and Environmental Health 1976; 2: 471–480
  • Reynolds W. A., Parsons L., Stegink L. D. Neuropathology studies following aspartame ingestion by infant nonhuman primates. Aspartame: Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 363–378
  • Reynolds W. A., Stegink L. D., Filer L. J., Jr., Renn E. Aspartame administration to the infant monkey: Hypothalamic morphology and plasma amino acid levels. Anatomical Record 1980; 198: 73–85
  • Robbins P. I., Raymond L. Aspartame and symptoms of carpal tunnel syndrome. Journal of Occupational and Environmental Medicine 1999; 41: 418
  • Roberts H. J. Reactions attributed to aspartame-containing products: 551 cases. Journal of Applied Nutrition 1988; 40: 85–94
  • Roberts H. J. Does aspartame (Nutrasweet). cause human brain cancer. Clinical Research 1990; 38: A798
  • Roberts H. J. Aspartame disease: A possible cause for concomitant Graves' disease and pulmonary hypertension. Texas Heart Institute Journal 2004; 31: 105
  • Rockhold R. W., Acuff C. G., Clower B. R. Excitotoxic lesions of the paraventricular hypothalamus: Metabolic and cardiac effects. Neuropharmacology 1990; 29: 663–673
  • Rogers P. J., Carlyle J. A., Hill A. J., Blundell J. E. Uncoupling sweet taste and calories: comparison of the effects of glucose and three intense sweeteners on hunger and food intake. Physiology and Behavior 1988; 43: 547–552
  • Roshon M. S., Hagen R. L. Sugar consumption, locomotion, task orientation, and learning in preschool children. Journal of Abnormal Child Psychology 1989; 17: 349–357
  • Ross J. A. Brain tumors and artificial sweeteners? A lesson on not getting soured on epidemiology. Medical and Pediatric Oncology 1998; 30: 7–8
  • Rowan A. J., Shaywitz B. A., Tuchman L., French J. A., Luciano D., Sullivan C. M. Aspartame and seizure susceptibility: results of a clinical study in reportedly sensitive individuals. Epilepsia 1995; 36: 270–275
  • Rowe R. C., Sheskey P. J., Weller P. J. Aspartame. Handbook of Pharmaceutical Excipients. 4th Edition. American Pharmaceutical Association, Washington, DC 2003; 37–39
  • Ryan-Harshman M., Leiter L. A., Anderson G. H. Phenylalanine and aspartame fail to alter feeding behavior, mood and arousal in men. Physiology and Behavior 1987; 39: 247–253
  • Sabah S., Scriba G. K.E. Determination of aspartame and its degradation and epimerization products by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 1998; 1998: 1089–1096
  • Saravis S., Schachar R., Zlotkin S., Leiter L. A., Anderson G. H. Aspartame: Effects on learning, behavior, and mood. Pediatrics 1990; 86: 75–83
  • Sargentini N. J., Smith K. C. Mutagenesis by normal metabolites in Escherichia coli: phenylalanine mutagenesis is dependent on error-prone DNA repair. Mutation Research 1986; 161: 113–118
  • Sasaki Y. F., Kawaguchi S., Kamaya A., Ohshita M., Kabasawa K., Iwama K., Taniguchi K., Tsuda S. The comet assay with 8 mouse organs: results with 39 currently used food additives. Mutation Research 2002; 519: 103–119
  • Saunders F. J., Pautsch W. F., Nutting E. F. The biological properties of aspartame. III. Examination for endocrine-like activities. Journal of Environmental Pathology and Toxicology 1980; 3: 363–373
  • Schainker B., Olney J. W. Glutamate-type hypothalamic-pituitary syndrome in mice treated with aspartate or cysteate in infancy. Journal of Neural Transmission 1974; 35: 207–215
  • Schiffman S. S., Buckley C. E., III, Sampson H. A., Massey E. W., Baraniuk J. N., Follett J. V., Warwick Z. S. Aspartame and susceptibility to headache. New England Journal of Medicine 1987; 317: 1181–1185
  • Schilling A., Danilova V., Hellekant G. Behavioral study in the gray mouse lemur (Microcebus murinus). using compounds considered sweet by humans. American Journal of Primatology 2004; 62: 43–48
  • Schroeder. SC-18862: An evaluation of the mutagenic potential in the rat employing the dominant lethal assay. Department of Biological Research (Pathology-Toxicology), Searle Laboratories, Chicago 1973, Pathology-Toxicology Project No.868H70
  • Schwartz G. R. Aspartame and breast and other cancers. Western Journal of Medicine 1999; 171: 300–301
  • Searle Laboratories. SC-18862: 104-Week toxicity study in the mouse. Hazleton Laboratories, Inc., Vienna, VA 1974, Final report. E-75. P-T No. 984H73
  • Seife C. Increasing brain tumor rates: Is there a link to deficit spending?. Journal of Neuropathology and Experimental Neurology 1999; 58: 404–405
  • Serrano M., Lee H. W., Chin L., Cordon-Cardo C., Beach D., DePinho R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27–37
  • Shahangian S., Ash K. O., Rollins D. E. Aspartame not a source of formate toxicity. Clinical Chemistry 1984; 30: 1264–1265
  • Sharma S., Jain N. K., Kulkarni S. K. Possible analgesic and anti-inflammatory interactions of aspartame with opioids and NSAIDs. Indian Journal of Experimental Biology 2005; 43: 498–502
  • Shaywitz B. A., Anderson G. M., Novotny E. J., Ebersole J. S., Sullivan C. M., Gillespie S. M. Aspartame has no effect on seizures or epileptiform discharges in epileptic children. Annals of Neurology 1994a; 35: 98–103
  • Shaywitz B. A., Novotny E. J., Jr. Aspartame and seizures. Neurology 1993; 43: 630–631
  • Shaywitz B. A., Sullivan C. M., Anderson G. M., Gillespie S. M., Sullivan B., Shaywitz S. E. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics 1994b; 93: 70–75
  • Sheehan T. G., Tully E. R. Purine biosynthesis de novo in rat skeletal muscle. Biochemical Journal 1983; 216: 605–610
  • Shephard S. E., Meier I., Lutz W. K. Alkylating potency of nitrosated amino acids and peptides. Relerance Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins, I. J. Chen, H. Bartsch. International Agency for Research on Cancer, IARC, LyonFrance 1991; 383–387
  • Shephard S. E., Wakabayashi K., Nagao M. Mutagenic activity of peptides and the artificial sweetener aspartame after nitrosation. Food and Chemical Toxicology 1993; 31: 323–329
  • Shigeta H., Yoshida T., Nakai M., Mori H., Kano Y., Nishioka H., Kajiyama S., Kitagawa Y., Kanatsuna T., Kondo M., Otsuki K. Effects of aspartame on diabetic rats and diabetic patients. Journal of Nutritional Science and Vitaminology (Tokyo) 1985; 31: 533–540
  • Simms H. S. Longevity studies in rats. I. Relation between life span and onset of specific lesions. Pathology of Laboratory Rats and Mice, E. Cotchin, J. F. C. Roe. Blackwell Scientific Publications, Oxford 1967; 733–747
  • Singleton M. J., Heiser C., Jamesen K., Mattes R. D. Sweetener augmentation of serum triacylglycerol during a fat challenge test in humans. Journal of the American College of Nutrition 1999; 18: 179–185
  • Smith J. D., Terpening C. M., Schmidt S. O., Gums J. G. Relief of fibromyalagia symptoms following discontinuation of dietary excitotoxins. Annals of Pharmacotherapy 2001; 35: 702–706
  • Smith Q. R. Transport of glutamate and other amino acids at the blood–brain barrier. Journal of Nutrition 2000; 130: 1016S–1022S
  • Soffritti M., Belpoggi F., Esposti D. D., Lambertini L., Tibaldi E., Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environmental Health Perspectives 2006; 114: 379–385
  • Soffritti M., Belpoggi F., Esposti D. D., Lambertini L. Aspartame induces lymphomas and leukaemias in rats. European Journal of Oncology 2005; 10: 107–116
  • Soffritti M., Belpoggi F., Minardi F., Maltoni C. Ramazzini Foundation cancer program: History and major projects, life-span carcinogenicity bioassay design, chemicals studied, and results. Annals of the New York Academy of Sciences 2002; 982: 26–45
  • Soffritti M., Maltoni C., Maffei F., Biagi R. Formaldehyde: An experimental multipotential carcinogen. Toxicology and Industrial Health 1989; 5: 699–730
  • Spencer P. S. Biological principles of chemical neurotixicity. Experimental and Clinical Neurotoxicology. 2nd Edition, P. S. Spencer, Oxford, New York 2000; 3–54
  • Sperber E. F., Moshe S. L., Dow-Edwards D. L. Prenatal exposure to aspartame and seizure susceptibility. Journal of Epilepsy 1995; 8: 51–56
  • Spiers P. A., Sabounjian L., Reiner A., Myers D. K., Wurtman J., Schomer D. L. Aspartame: Neuropsychologic and neurophysiologic evaluation of acute and chronic effects. American Journal of Clinical Nutrition 1998; 68: 531–537
  • Stedman's Medical Dictionary. Coloboma. Williams & Wilkins, Baltimore, MD 1995a; 366
  • Stedman's Medical Dictionary. EEG. Williams & Wilkins, Baltimore, MD 1995b; 545
  • Stedman's Medical Dictionary, 26th Edition. Williams & Wilkins, Baltimore, MD 1995c; 887
  • Stedman's Medical Dictionary. Kindling. Williams & Wilkins, Baltimore, MD 1995d; 920
  • Stedman's Medical Dictionary, 26th Edition. Meningitis. Williams & Wilkins, Baltimore, MD 1995e; 1087
  • Stedman's Medical Dictionary. Myoclonus. Williams & Wilkins, Baltimore, MD 1995f; 1168
  • Stedman's Medical Dictionary. Panniculitis. Williams & Wilkins, Baltimore, MD 1995g; 1288
  • Stedman's Medical Dictionary, 26th Edition. Williams & Wilkins, Baltimore, MD 1995h; 1323, Pentylenetetrazol
  • Stedman's Medical Dictionary, 26th Edition. Williams & Wilkins, Baltimore, MD 1995i; 1326, Pericarditis
  • Stedman's Medical Dictionary, 26th Edition. Williams & Wilkins, Baltimore, MD 1995j; 1333, Peritonitis
  • Stedman's Medical Dictionary. Williams & Wilkins, Baltimore, MD 1995k; 1348, Phenylketonuria (PKU)
  • Stedman's Medical Dictionary Pleuritis. 26th Edition. Williams & Wilkins, Baltimore, MD 1995l; 1382–1383
  • Stedman's Medical Dictionary, Pyelonephritis. 26th Edition. Williams & Wilkins, Baltimore, MD 1995m; 1471
  • Stedman's Medical Dictionary, 26th Edition. Williams & Wilkins, Baltimore, MD 1995n; 1480, Quinolinic acid
  • Stedman's Medical Dictionary. Williams & Wilkins, Baltimore, MD 1995o; 1895–1896, Urticaria
  • Stegink L. D. Aspartame metabolism in humans: Acute dosing studies. Aspartame. Physiology and Biochemistry, L. D. Stegink, L. J. Filer, Jr. Marcel Dekker, New York 1984; 509–553
  • Stegink L. D. The aspartame story: A model for the clinical testing of a food additive. American Journal of Clinical Nutrition 1987; 46: 204–215
  • Stegink L. D., Brummel M. C., Filer L. J., Jr., Baker G. L. Blood methanol concentrations in one-year-old infants administered graded doses of aspartame. Journal of Nutrition 1983a; 113: 1600–1606
  • Stegink L. D., Brummel M. C., McMartin K., Martin-Amat G., Filer L. J., Jr., Baker G. L., Tephly T. R. Blood methanol concentrations in normal adult subjects administered abuse doses of aspartame. Journal of Toxicology and Environmental Health 1981a; 7: 281–290
  • Stegink L. D., Brummel M. C., Persoon T. J., Filer L. J., Jr., Bell E. F., Ziegler E. E. Effect of sucrose on the metabolic disposition of aspartame. American Journal of Clinical Nutrition 1990; 52: 335–341
  • Stegink L. D., Filer L. J., Jr. Effects of aspartame ingestion on plasma aspartate, phenylalanine, and methanol concentrations in potentially sensitive populations. The Clinical Evaluation of a Food Additive: Assessment of Aspartame, C. Tschanz, H. H. Butchko, W. W. Stargel, F. N. Kotsonis. CRC Press, Boca Raton, FL 1996; 87–113
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Effect of aspartame and aspartate loading upon plasma and erythrocyte free amino acid levels in normal adult volunteers. Journal of Nutrition 1977; 107: 1837–1845
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Plasma, erythrocyte and human milk levels of free amino acids in lactating women administered aspartame or lactose. Journal of Nutrition 1979; 109: 2173–2181
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Plasma and erythrocyte concentrations of free amino acids in adult humans administered abuse doses of aspartame. Journal of Toxicology and Environmental Health 1981b; 7: 291–305
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Plasma amino acid concentrations in normal adults fed meals with added monosodium L-glutamate and aspartame. Journal of Nutrition 1983b; 113: 1851–1860
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Plasma amino acid concentrations in normal adults ingesting aspartame and monosodium L-glutamate as part of a soup/beverage meal. Metabolism 1987; 36: 1073–1079
  • Stegink L. D., Filer L. J., Jr., Baker G. L. Repeated ingestion of aspartame-sweetened beverage: Effect on plasma amino acid concentrations in normal adults. Metabolism 1988; 37: 246–251
  • Stegink L. D., Filer L. J., Jr., Bell E. F., Ziegler E. E., Tephly T. R. Effect of repeated ingestion of aspartame-sweetened beverage on plasma amino acid, blood methanol, and blood formate concentrations in normal adults. Metabolism 1989; 38: 357–363
  • Stegink L. D., Lindgren S. D., Brummel M. C., Stumbo P. J., Wolraich M. L. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. American Journal of Clinical Nutrition 1995; 62: 1206–1211
  • Stokes A. F., Belger A., Banich M. T., Bernadine E. Effects of alcohol and chronic aspartame ingestion upon performance in aviation relevant cognitive tasks. Aviation, Space, and Environmental Medicine 1994; 65: 7–15
  • Stokes A. F., Belger A., Banich M. T., Taylor H. Effects of acute aspartame and acute alcohol ingestion upon the cognitive performance of pilots. Aviation, Space, and Environmental Medicine 1991; 62: 648–653
  • Storer R. D., French J. E., Haseman J., Hajian G., LeGrand E. K., Long G. G., Mixson L. A., Ochoa R., Sagartz J. E., Soper K. A. P53+/– hemizygous knockout mouse: overview of available data. Toxicologic Pathology 2001; 30–50, (29 Suppl.)
  • Strong F. C., III. Why do some dietary migraine patients claim they get headaches from placebos?. Clinical and Experimental Allergy 2000; 30: 739–743
  • Sunram-Lea S. I., Foster J. K., Durlach P., Perez C. Glucose facilitation of cognitive performance in healthy young adults: Examination of the influence of fast-duration, time of day and pre-consumption plasma glucose levels. Psychopharmacology (Berlin) 2001; 157: 46–54
  • Sunram-Lea S. I., Foster J. K., Durlach P., Perez C. Investigation into the significance of task difficulty and divided allocation of resources on the glucose memory facilitation effect. Psychopharmacology (Berlin) 2002; 160: 387–397
  • Sunram-Lea S. I., Foster J. K., Durlach P., Perez C. The influence of fat co-administration on the glucose memory facilitation effect. Nutritional Neuroscience 2004; 7: 21–32
  • Sweetman S. C. Aspartame. Nutritional Agents and Vitamins. Martindale. The complete drug reference. 33rd Edition. Pharmaceutical Press, London 2002; 1354
  • Sze P. Y. Pharmacological effects of phenylalanine on seizure susceptibility: An overview. Neurochemical Research 1989; 14: 103–111
  • Takasaki Y., Iwata S., Torii K. Drinking behavior and the development of hypothalamic lesions from aspartame ingestion in water-restricted weanling mice. Journal of Neural Transmission 1981; 50: 283–295
  • Taucher J., Lagg A., Hansel A., Vogel W., Lindinger W. Methanol in human breath. Alcoholism, Clinical and Experimental Research 1995; 19: 1147–1150
  • Tennant R. W., French J. E., Spalding J. W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environmental Health Perspectives 1995; 103: 942–950
  • Tennant R. W., Stasiewicz S., Eastin W. C., Mennear J. H., Spalding J. W. The Tg.AC (v-Ha-ras). transgenic mouse: Nature of the model. Toxicologic Pathology 2001; 51–59, (29 Suppl.)
  • Tennant R. W., Tice R. R., Spalding J. W. The transgenic Tg.AC mouse model for identification of chemical carcinogens. Toxicology Letters 1998; 102–103: 465–471
  • Thomas-Dobersen D. Calculation of aspartame intake in children. Journal of the American Dietetic Association 1989; 89: 831–833
  • Tilson H. A., Hong J. S., Sobotka T. J. High doses of aspartame have no effects on sensorimotor function or learning and memory in rats. Neurotoxicology and Teratology 1991; 13: 27–35
  • Tilson H. A., Thai L., Zhao D., Sobotka T. J., Hong J. S. Oral administration of aspartame is not proconvulsant in rats. Neurotoxicology 1989; 10: 229–238
  • Toledo M. C., Ioshi S. H. Potential intake of intense sweeteners in Brazil. Food Additives and Contaminants 1995; 12: 799–808
  • Tollefson L. Monitoring adverse reactions to food additives in the U.S. Food and Drug Administration. Regulatory Toxicology and Pharmacology 1988; 8: 438–446
  • Tollefson L., Barnard R. J. An analysis of FDA passive surveillance reports of seizures associated with consumption of aspartame. Journal of the American Dietetic Association 1992; 92: 598–601
  • Tollefson L., Barnard R. J., Glinsmann W. H. Dietary Phenylalanine and Brain Function, R. J. Wurtman, E. Ritter-Walker. Birkhauser Boston, Inc., New York, NY 1988; 317–337, between Administration
  • Torii K., Mimura T., Takasaki Y., Ichimura M. Dietary aspartame with protein on plasma and brain amino acids, brain monoamines and behavior in rats. Physiology and Behavior 1986; 36: 765–771
  • Trichopoulos D. Aspartame and breast and other cancers. Response. Western Journal of Medicine 1999; 171: 301
  • Trutter J. A., Reno F. E. SC-18862: Two-year toxicity study in the rat. Hazleton Laboratories, Inc., Vienna, VA 1973, Final report. E-33 and E-34 Report P-T No. 838H71
  • Tsakiris S., Giannoulia-karantana A., Simintzi I., Schulpis K. H. The effect of aspartame metabolites on human erythrocyte membrane acetylcholinesterase activity. Pharmacological Research 2006; 53: 1–5
  • Tutelyan V. A., Kravchenko L. V., Kuzmina E. E. The effect of aspartame on the activity of rat liver xenobiotic-metabolizing enzymes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1990; 18: 223–225
  • Vaclavik V. A., Christian E. W. Essentials of Food Science. 2nd Edition. Kluwer Academic Publishers, New York 2003; 27
  • Van den Eeden S. K., Koepsell T. D., Longstreth W. T., Jr., van Belle G., Daling J. R., McKnight B. Aspartame ingestion and headaches: A randomized crossover trial. Neurology 1994; 44: 1787–1793
  • van der Laan J., Lima B. S., Snodin D. Alternatives models in carcinogenicity testing—A European perspective. Toxicologic Pathology 2002; 30: 157–159
  • VCF. Methanol. Database of Volatile Compounds in Food. TNO Nutrition and Food Research, Boelens Aroma Chemical Information Service, ZeistThe Netherlands 1999, CD-ROM
  • Vences-Mejia A., Labra-Ruiz N., Hernandez-Martinez N., Dorado-Gonzalez V., Gomez-Garduno J., Perez-Lopez I., Nosti-Palacios R., Camacho Carranza R., Espinosa-Aguirre J. J. The effect of aspartame on rat brain xenobiotic-metabolizing enzymes. Human & Experimental Toxicology 2006; 25: 453–459
  • Venkatachalam S., Tyner S. D., Pickering C. R., Boley S., Recio L., French J. E., Donehower L. A. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/– mouse model in carcinogenicity testing. Toxicologic Pathology 2001; 29: 147–154
  • Virani S. S., Mendoza C. E., Ferreira A. C., de Marchena E. Graves' disease and pulmonary hypertension: Report of 2 cases. Texas Heart Institute Journal 2003; 30: 314–315
  • Wall K. M., Pardridge W. M. Decreases in brain protein synthesis elicited by moderate increases in plasma phenylalanine. Biochemical and Biophysical Research Communications 1990; 168: 1177–1183
  • Walton R. G. The possible role of aspartame in seizure induction. Dietary Phenylalanine and Brain Function, R. J. Wurtman, E. Ritter-Walker. Birkhauser Boston, Inc., New York, NY 1988; 159–162
  • Walton R. G., Hudak R., Green-Waite R. J. Adverse reactions to aspartame: Double-blind challenge in patients from a vulnerable population. Biological Psychiatry 1993; 34: 13–17
  • Wang C. S. Induction of RNA C-type viruses by artificial sweeteners. Scientific note. Proceedings of the National Science Council, Republic of China 1980; 4: 424–427
  • Ward J. M., Rhem S., Reynolds C. W. Tumors of the haematopoietic system. Pathology of Tumors in Laboratory Animals. Volume 1—Tumors of the Rat, Second Edition, V. Turusov, U. Mohr, Lyon 1990; 625–657, IARC Scientific Publications No. 99
  • Weihrauch M. R., Diehl V. Artificial sweeteners—Do they bear a carcinogenic risk?. Annals of Oncology 2004; 15: 1460–1465
  • Wolraich M., Milich R., Stumbo P., Schultz F. Effects of sucrose ingestion on the behavior of hyperactive boys. Journal of Pediatrics 1985; 106: 675–682
  • Wolraich M. L., Lindgren S. D., Stumbo P. J., Stegink L. D., Appelbaum M. I., Kiritsy M. C. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. New England Journal of Medicine 1994; 330: 301–307
  • Wurtman R. J. Neurochemical changes following high-dose aspartame with dietary carbohydrates. New England Journal of Medicine 1983; 309: 429–430
  • Wurtman R. J., Maher T. J. Effects of oral aspartame on plasma phenylalanine in humans and experimental rodents. Short note. Journal of Neural Transmission 1987; 70: 169–173
  • Wyss C. Aspartame as a source of essential phenylalanine for the growth of oral anaerobes. FEMS Microbiology Letters 1993; 108: 255–258
  • Xu H., Staszewski L., Tang H., Adler E., Zoller M., Li X. Different functional roles of T1R subunits in the heteromeric taste receptors. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 14258–14263
  • Yokogoshi H., Roberts C. H., Caballero B., Wurtman R. J. Effects of aspartame and glucose administration on brain and plasma levels of large neutral amino acids and brain 5-hydroxyindoles. American Journal of Clinical Nutrition 1984; 40: 1–7
  • Yokogoshi H., Wurtman R. J. Acute effects of oral or parenteral aspartame on catecholamine metabolism in various regions of rat brain. Journal of Nutrition 1986; 116: 356–364
  • Yost D. A. Clinical safety of aspartame. American Family Physician 1989; 39: 201–206
  • Zametkin A. J., Karoum F., Rapoport J. L. Treatment of hyperactive children with D-phenylalanine. American Journal of Psychiatry 1987; 144: 792–794
  • Zhang C., Bordet S., Karoum F., Commissiong J. W. Effect of precursors on the synthesis of catecholamines and on neurotransmission in the superior cervical ganglion of the rat. Journal of Neurochemistry 1990; 55: 890–898
  • Zhi J. Q., Levy G. Aspartame and phenylalanine do not enhance theophylline-induced seizures in rats. Research Communications in Chemical Pathology and Pharmacology 1989; 66: 171–174

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.